Insys NDA set to increase crowding in US fentanyl market
This article was originally published in Scrip
Executive Summary
Insys Therapeutics, a biopharmaceutical company focused on developing products to address chemotherapy-induced nausea and vomiting, pain management and other CNS disorders, has submitted a new drug application with the US FDA for its investigational cancer pain product candidate, fentanyl sublingual spray.